Teva Pharmaceutical Industries Limited

TEVANYSEHealthcare● Active

$34.19

$-0.24(-0.70%)

Market Cap$39.8B

P/E Ratio—

52W High$37.35

52W Low$14.99

Avg Volume6.7M

Open$34.30

Beta0.85

Cash on Hand Financials Revenue

Teva Pharmaceutical Industries Limited (TEVA) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

TEVA · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$3.56B▲ +7.8% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$3.56B

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+7.8%

vs prior fiscal year

Latest Quarter

$3.74B

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$3.56BCash on Hand

Total Debt$17.38BTotal Debt

Net Cash / Net Debt−$13.83BNet Debt Position

Cash vs Debt Ratio

Cash 17%Teva Pharmaceutical Industries Limited cash as % of market cap: 8.93%% · MCap $40BDebt 83%

Teva Pharmaceutical Industries Limited carries a net debt position of $13.83B. Total debt ($17.38B) exceeds cash on hand ($3.56B). Teva Pharmaceutical Industries Limited cash vs debt ratio: 17% cash / 83% debt.

Net Cash = Cash & ST Investments − Total Debt$3.56B − $17.38B = −$13.83B

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

TEVA annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

TEVA cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$3.56B+7.8%

Dec 31, 2024FY$3.30B+2.3%

Dec 31, 2023FY$3.23B+15.2%

Dec 31, 2022FY$2.80B+29.4%

Dec 31, 2021FY$2.17B-0.6%

TEVA cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

TEVA vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Teva Pharmaceutical Industries LimitedYOU

TEVA

$3.56B$40B8.9%

13%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Teva Pharmaceutical Industries Limited (TEVA) cash on hand as of December 31, 2025 is $3.56B, comprising $3.56B in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Teva Pharmaceutical Industries Limited cash and short-term investments on the balance sheet (10-K filing). Also referred to as Teva Pharmaceutical Industries Limited cash reserves or cash position.

Teva Pharmaceutical Industries Limited annual cash on hand history shows increased +7.8% in 2025: increased +7.8% in 2025. Teva Pharmaceutical Industries Limited cash reserves in 2025 reflect the company's capital allocation strategy.

Teva Pharmaceutical Industries Limited carries total debt of $17.38B against cash of $3.56B, resulting in a net debt position of -$13.83B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

TEVA cash on hand · 5 questions

As of December 31, 2025, Teva Pharmaceutical Industries Limited (TEVA) has $3.56B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $3.56B in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $3.74B. Data sourced from the annual 10-K filing via FMP.

TEVA cash on handTEVA cash reservesTEVA cash 2025how much cash does TEVA have

▸ Source: FMP /balance-sheet-statement · US GAAP · Teva Pharmaceutical Industries Limited · Teva Pharmaceutical Industries Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025